A Novel Method for Creating a Synthetic L-DOPA Proteome and In Vitro Evidence of Incorporation

Overview

Journal Proteomes

Date 2021 Jun 2

PMID 34073856

Citations 2

Authors

Joel Ricky Steele

Natalie Strange

Kenneth J Rodgers

Matthew P Padula

Affiliations

Soon will be listed here.

Abstract

Proteinopathies are protein misfolding diseases that have an underlying factor that affects the conformation of proteoforms. A factor hypothesised to play a role in these diseases is the incorporation of non-protein amino acids into proteins, with a key example being the therapeutic drug levodopa. The presence of levodopa as a protein constituent has been explored in several studies, but it has not been examined in a global proteomic manner. This paper provides a proof-of-concept method for enzymatically creating levodopa-containing proteins using the enzyme tyrosinase and provides spectral evidence of in vitro incorporation in addition to the induction of the unfolded protein response due to levodopa.

Citing Articles

L-DOPA Autoxidation: An Empirical Valence Bond Simulation of the Reactive Step.

Prah A, Mavri J J Phys Chem B. 2024; 128(35):8355-8361.

PMID: 39180475 PMC: 11382278. DOI: 10.1021/acs.jpcb.4c03002.

Enzymatic Phosphorylation of Oxidized Tyrosine Residues.

Heininen J, Erbacher C, Kotiaho T, Kostiainen R, Teppo J J Proteome Res. 2023; 22(6):1959-1968.

PMID: 37146082 PMC: 10243104. DOI: 10.1021/acs.jproteome.3c00061.

References

Rascol O, Payoux P, Ory F, Ferreira J, Brefel-Courbon C, Montastruc J . Limitations of current Parkinson's disease therapy. Ann Neurol. 2003; 53 Suppl 3:S3-12; discussion S12-5. DOI: 10.1002/ana.10513. View

Ito S, Kato T, SHINPO K, Fujita K . Oxidation of tyrosine residues in proteins by tyrosinase. Formation of protein-bonded 3,4-dihydroxyphenylalanine and 5-S-cysteinyl-3,4-dihydroxyphenylalanine. Biochem J. 1984; 222(2):407-11. PMC: 1144193. DOI: 10.1042/bj2220407. View

Kostrzewa R, Kostrzewa J, Brus R . Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease. Amino Acids. 2002; 23(1-3):57-63. DOI: 10.1007/s00726-001-0110-x. View

Koh S, Park H, Choi N, Lee K, Kim S, Lee Y . Protective effects of statins on L-DOPA neurotoxicity due to the activation of phosphatidylinositol 3-kinase and free radical scavenging in PC12 cell culture. Brain Res. 2010; 1370:53-63. DOI: 10.1016/j.brainres.2010.11.021. View

Dunlop R, Brunk U, Rodgers K . Proteins containing oxidized amino acids induce apoptosis in human monocytes. Biochem J. 2011; 435(1):207-16. DOI: 10.1042/BJ20100682. View

Asanuma M, Miyazaki I, Ogawa N . Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease. Neurotox Res. 2003; 5(3):165-76. DOI: 10.1007/BF03033137. View

Basma A, Morris E, Nicklas W, Geller H . L-dopa cytotoxicity to PC12 cells in culture is via its autoxidation. J Neurochem. 1995; 64(2):825-32. DOI: 10.1046/j.1471-4159.1995.64020825.x. View

Cienska M, Labus K, Lewanczuk M, Kozlecki T, Liesiene J, Bryjak J . Effective L-Tyrosine Hydroxylation by Native and Immobilized Tyrosinase. PLoS One. 2016; 11(10):e0164213. PMC: 5053437. DOI: 10.1371/journal.pone.0164213. View

Mytilineou C, Han S, Cohen G . Toxic and protective effects of L-dopa on mesencephalic cell cultures. J Neurochem. 1993; 61(4):1470-8. DOI: 10.1111/j.1471-4159.1993.tb13642.x. View

10.

Pedrosa R, Soares-da-Silva P . Oxidative and non-oxidative mechanisms of neuronal cell death and apoptosis by L-3,4-dihydroxyphenylalanine (L-DOPA) and dopamine. Br J Pharmacol. 2002; 137(8):1305-13. PMC: 1573607. DOI: 10.1038/sj.bjp.0704982. View

11.

Walker E, Bettinger J, Welle K, Hryhorenko J, Ghaemmaghami S . Global analysis of methionine oxidation provides a census of folding stabilities for the human proteome. Proc Natl Acad Sci U S A. 2019; 116(13):6081-6090. PMC: 6442572. DOI: 10.1073/pnas.1819851116. View

12.

Jami M, Pal R, Hoedt E, Neubert T, Larsen J, Moller S . Proteome analysis reveals roles of L-DOPA in response to oxidative stress in neurons. BMC Neurosci. 2014; 15:93. PMC: 4125692. DOI: 10.1186/1471-2202-15-93. View

13.

Ho P, Ho J, Liu H, So D, Tse Z, Chan K . Mitochondrial neuronal uncoupling proteins: a target for potential disease-modification in Parkinson's disease. Transl Neurodegener. 2012; 1(1):3. PMC: 3506996. DOI: 10.1186/2047-9158-1-3. View

14.

Rodgers K, Wang H, Fu S, Dean R . Biosynthetic incorporation of oxidized amino acids into proteins and their cellular proteolysis. Free Radic Biol Med. 2002; 32(8):766-75. DOI: 10.1016/s0891-5849(02)00768-2. View

15.

Vincent S, Cunningham P, Stephens N, Halayko A, Fisher J . Quantitative densitometry of proteins stained with coomassie blue using a Hewlett Packard scanjet scanner and Scanplot software. Electrophoresis. 1997; 18(1):67-71. DOI: 10.1002/elps.1150180114. View

16.

Dunlop R, Dean R, Rodgers K . The impact of specific oxidized amino acids on protein turnover in J774 cells. Biochem J. 2007; 410(1):131-40. DOI: 10.1042/BJ20070161. View

17.

Ozawa K, Headlam M, Mouradov D, Watt S, Beck J, Rodgers K . Translational incorporation of L-3,4-dihydroxyphenylalanine into proteins. FEBS J. 2005; 272(12):3162-71. DOI: 10.1111/j.1742-4658.2005.04735.x. View

18.

Kang I, Chu C, Kaufman B . The mitochondrial transcription factor TFAM in neurodegeneration: emerging evidence and mechanisms. FEBS Lett. 2018; 592(5):793-811. PMC: 5851836. DOI: 10.1002/1873-3468.12989. View

19.

Chan S, Dunlop R, Rowe A, Double K, Rodgers K . L-DOPA is incorporated into brain proteins of patients treated for Parkinson's disease, inducing toxicity in human neuroblastoma cells in vitro. Exp Neurol. 2011; 238(1):29-37. DOI: 10.1016/j.expneurol.2011.09.029. View

20.

Hwang D, Gim Y, Yoo H, Cha H . Practical recombinant hybrid mussel bioadhesive fp-151. Biomaterials. 2007; 28(24):3560-8. DOI: 10.1016/j.biomaterials.2007.04.039. View